NRC committee weighs radiopharmaceutical safety, AI oversight, new guidance

The rule that could move the needle

The most consequential question in the room was not abstract safety theory. It was whether NRC will let authorized users handle parenteral alpha-emitting radiopharmaceuticals for therapy without extra case-specific training, a change that could strip away one of the last regulatory frictions before these treatments move deeper into routine clinical use.

If that guidance stands, the difference will show up fast in real workflows. Nuclear medicine departments would have a cleaner path to bring the therapy online, radiopharmacies would have fewer training hurdles to document, and patients could see less delay between a referral and an actual treatment slot. In a field where access often depends on whether a center can clear the paperwork as fast as it can clear the dose, that matters.

What ACMUI put on the table

The Advisory Committee on the Medical Uses of Isotopes met April 20 and 21 in the ACRS conference room at Two White Flint North in North Bethesda, Maryland, with the April 20 session beginning at 9:00 a.m. Eastern and the April 21 session running from 10:00 a.m. to 1:30 p.m. Eastern. The meeting was open to the public in person and by Microsoft Teams, with some sessions allowed to close for privacy or pre-decisional reasons, and it included a public Commission briefing on April 21.

The agenda was broad, but it was not random. ACMUI planned to review medical events, weigh subcommittee recommendations tied to the ADVANCE Act mission statement, consider proposed guidance for licensing alpha-emitting radiopharmaceutical therapies, and receive updates from the NRC’s Medical Radiation Safety Team. It also set aside time for artificial intelligence and deep-learning tools, plus a tentative discussion of modernizing physical-protection requirements for category 1 and category 2 quantities of radioactive material.

That mix tells you where the pressure is coming from. The committee is not just tidying up policy language. It is being asked to help NRC keep pace with therapies that are more targeted, more potent, and more operationally sensitive than the older nuclear medicine playbook.

Why the alpha-therapy question is the one to watch

The draft NRC memo reviewed by ACMUI is the key document here. It says authorized users under 10 CFR 35.390 or 35.396 could use parenteral alpha-emitting radiopharmaceuticals for therapy without additional case-specific training because the radiation safety risks are considered comparable to beta or low-energy photon emitters.

That is a big deal because training language often becomes the real gatekeeper. A therapy can be scientifically ready, clinically promising, and commercially available, yet still crawl into practice if the licensing and training expectations are too awkward for hospitals to absorb. NRC’s own emerging-medical-technologies guidance says its licensing approach in this area includes general licensing considerations, radiation safety aspects, and training-and-experience expectations, so any shift in the alpha guidance would ripple through all three layers at once.

For doctors, the practical impact is simple: less friction in deciding whether a center can administer the therapy under existing authority. For pharmacists and radiation safety staff, it means fewer bespoke sign-offs to build into the workflow. For patients, especially those outside the biggest academic centers, it can mean the difference between local access and another long referral chain.

Where Part 35 still sets the floor

All of this sits inside NRC’s Part 35 framework, the federal rule set that governs the medical use of byproduct material and is meant to protect workers, the general public, patients, and human research subjects. That framework is the base layer for how radioactive material is ordered, stored, prepared, administered, and tracked in the clinic.

The reason ACMUI matters is that it helps NRC interpret how those protections should evolve when the technology moves faster than the rulebook. Alpha-emitting radiopharmaceuticals are exactly that kind of test case. They are not a novelty item for specialists anymore; they are becoming part of the serious conversation about modern cancer therapy, and the committee is being asked whether the existing training model is enough for them.

AI was not a sideshow

The committee also put artificial intelligence and deep-learning tools on the agenda, and that is not a random buzzword add-on. NRC has its own AI page describing how it defines AI and outlining ongoing work, and an earlier NRC AI report recommended a framework and identified use cases. The agency is clearly trying to decide where automation can support oversight without blurring responsibility.

In medical regulation, that distinction is everything. If AI is used to help sort reports, flag anomalies, or support decision-making, regulators will want traceability, accountability, and a clean audit trail. A tool can assist the process, but it cannot be allowed to become a black box in a field where dose, timing, and patient instructions have to be right the first time.

Who is in the committee room

ACMUI is built to keep the whole ecosystem in view. Its membership includes a nuclear medicine physician, a nuclear cardiologist, medical physicists, a radiation safety officer, a nuclear pharmacist, radiation oncologists, a patients’ rights advocate, an FDA representative, an Agreement State representative, a health care administrator, and a diagnostic radiologist. The roster also includes names such as Hossein Jadvar, Christopher Palestro, and Maryann Ayoade, which gives the committee the kind of cross-disciplinary mix this topic demands.

The agenda even included a look at whether ACMUI should propose adding an interventional radiologist. That suggestion makes sense in a year when procedural medicine, imaging, and radiopharmaceutical delivery keep overlapping more tightly. The committee was originally officially named in 1959 and was established under the authority of the Atomic Energy Act of 1954, so it has been adapting to new forms of medical use for a long time. This meeting showed that the adaptation is still underway.

The practical takeaway

The tentative physical-protection item may matter later if the rulemaking schedule lines up, but the immediate operational story is the alpha-therapy guidance. If NRC moves it forward, the people who will notice first are the ones who live with the workflow every day: the nuclear medicine staff trying to clear a therapy, the pharmacy team documenting handling and training, and the patient waiting for a slot that should not be stuck in regulatory limbo.

That is why this ACMUI meeting stood out. It was not just a committee checking boxes. It was a snapshot of NRC trying to decide how much friction the next generation of radiopharmaceutical therapy should carry, and how much room there is for AI to help without compromising the chain of accountability that nuclear medicine still runs on.